Fecal microbiota transplantation through colonoscopy in the treatment of recurrent Clostridioides difficile: Experience at a university center

被引:0
|
作者
Quera, R. [1 ]
Nunez, P. [1 ,2 ]
von Muhlenbrock, C. [1 ,3 ]
Espinoza, R. [4 ]
机构
[1] Univ Los Andes, Clin Univ Los Andes, Ctr Enfermedades Digest, Med Interna, Santiago, Chile
[2] Univ Chile, Hosp San Juan de Dios, Fac Med Occidente, Secc Gastroenterol, Santiago, Chile
[3] Hosp Clin Univ Chile, Dept Med, Secc Gastroenterol, Santiago, Chile
[4] Univ Los Andes, Clin Univ Los Andes, Secc Infectol, Med Interna, Santiago, Chile
来源
REVISTA DE GASTROENTEROLOGIA DE MEXICO | 2024年 / 89卷 / 04期
关键词
Clostridioides difficile; Fecal microbiota transplantation; Colonoscopy; Third age; Pregnancy; INFECTION; DIAGNOSIS; FROZEN; FRESH; RISK;
D O I
10.1016/j.rgmx.2024.03.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction: The majority of cases of Clostridioides difficile infection (CDI) respond to antibiotic treatment. Fecal microbiota transplantation (FMT) has been accepted as an effective treatment in cases of recurrent CDI. Aim: Our aim was to describe the clinical results of FMT performed for the treatment of recurrent CDI. Material and methods: The study was conducted on patients with recurrent CDI treated with FMT through colonoscopy, within the time frame of January 2021 and December 2023. Demographic and clinical data were collected, including pre-FMT treatment data, the FMT success rate, and clinical progression during follow-up. Telephone surveys were carried out to evaluate satisfaction. Results: Thirteen patients with a mean age of 55 years underwent FMT (including 7 patients above 65 years of age and one pregnant woman). Patients presented with a median of 3 previous episodes of CDI (range 2-4). The median time interval from first episode of CDI to FMT was 4 months (range 3-10). The effectiveness of a single FMT session was 100%. During post-FMT follow-up (median of 11 months, range 3-32), 3 patients have presented with a new CDI episode, and a successful second FMT was performed on 2 of them. No adverse events were registered, and all patients had a positive perception of FMT. Conclusions: In the present study, despite its small size, FMT through colonoscopy was shown to be a safe, effective, and lasting therapy in cases of recurrent CDI, concurring with results from larger studies. (c) 2024 Asociacion Mexicana de Gastroenterolog<acute accent>& imath;a. Published by Masson Doyma Mexico S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/).
引用
收藏
页码:513 / 520
页数:8
相关论文
共 50 条
  • [31] Fecal microbiota transplantation for recurrent Clostridioides difficile infection in frail and very old patients
    Montalto, Massimo
    Gallo, Antonella
    Agnitelli, Maria Chiara
    Pellegrino, Simona
    Lipari, Alice
    Pero, Erika
    Covino, Marcello
    Landi, Francesco
    Gasbarrini, Antonio
    Cammarota, Giovanni
    Ianiro, Gianluca
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 (11) : 3530 - 3537
  • [32] Fecal microbiota transplantation in an older patient with Clostridioides difficile recurrent infection. Report of one case
    Nunez, Paulina
    Quera, Rodrigo
    Von Muhlenbrock, Christian
    Concha, Alexandra
    Flores, Katherine
    REVISTA MEDICA DE CHILE, 2022, 150 (10) : 1396 - 1400
  • [33] Fecal microbiota transplantation: the need for effective treatment of Clostridioides difficile infection in Pakistan
    Khurram, Subata
    Asad, Ayesha
    Fatima, Syeda Zainab
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2023, 17 (11): : 1626 - 1627
  • [34] Successful use of early, repeat fecal microbiota transplantation for initial treatment of severe, refractory Clostridioides difficile colitis
    Cappetto, Catherine M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (15) : 1374 - 1381
  • [35] Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
    de la Villa, Sofia
    Herrero, Sergio
    Munoz, Patricia
    Rodriguez, Carmen
    Valerio, Maricela
    Reigadas, Elena
    Alvarez-Uria, Ana
    Alcala, Luis
    Marin, Mercedes
    Olmedo, Maria
    Kestler, Martha
    Chamorro, Esther
    Bouza, Emilio
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (02):
  • [36] Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection
    Hvas, Christian Lodberg
    Jorgensen, Simon Mark Dahl
    Jorgensen, Soren Peter
    Storgaard, Merete
    Lemming, Lars
    Hansen, Mette Mejlby
    Erikstrup, Christian
    Dahlerup, Jens Frederik
    GASTROENTEROLOGY, 2019, 156 (05) : 1324 - +
  • [37] Fecal Microbiota Transplantation for Treatment of Severe Clostridioides difficile Colitis in a Pediatric Patient With Non-Hodgkin Lymphoma
    Sabus, Ashley
    Merrow, Mya
    Heiden, Alyssa
    Boster, Julia
    Koo, Jane
    Franklin, Anna R. K.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (06) : E897 - E899
  • [38] Fecal microbiota transplantation as therapy for recurrent Clostridioides difficile infection is associated with amelioration of delirium and accompanied by changes in fecal microbiota and the metabolome
    Gotoh, Kazuyoshi
    Sakaguchi, Yoshihiko
    Kato, Haru
    Osaki, Hayato
    Jodai, Yasutaka
    Wakuda, Mitsutaka
    Take, Akira
    Hayashi, Shunji
    Morita, Eri
    Sugie, Takehiko
    Ito, Yoichiro
    Ohmiya, Naoki
    ANAEROBE, 2022, 73
  • [39] Efficacy and safety of commercialized fecal microbiota transplant for the treatment of recurrent Clostridioides difficile infection
    Yendrapalli, Usha
    Edwards, Jonathan
    Belk, Madeline
    Steuber, Taylor
    Hassoun, Ali
    INFECTION DISEASE & HEALTH, 2023, 28 (01) : 71 - 73
  • [40] Fecal Microbiota Transplantation (FMT) with Colonoscopy Is Superior to Enema and Nasogastric Tube While Comparable to Capsule for the Treatment of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis
    Daryl Ramai
    Karl Zakhia
    Paul J. Fields
    Andrew Ofosu
    Goonja Patel
    Vahe Shahnazarian
    Jonathan K. Lai
    Amaninder Dhaliwal
    Madhavi Reddy
    Shannon Chang
    Digestive Diseases and Sciences, 2021, 66 : 369 - 380